CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company focused on bringing transformative therapies to patients with rare diseases, today announced that Catabasis will present CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD) and the MoveDMDSM trial design at the XIV International Conference on Duchenne and Becker Muscular Dystrophy. The conference will be held February 13 – 14, 2016, in Rome, Italy, at the Church Palace.
